Cybin shares are trading higher after the company announced it completed enrollment in its Phase 2 study of CYB003.
Portfolio Pulse from Benzinga Newsdesk
Cybin Inc. has completed enrollment in its Phase 2 study of CYB003, leading to a rise in its share prices.
September 21, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cybin's stock price is likely to increase in the short term due to the completion of enrollment in its Phase 2 study of CYB003.
The completion of enrollment in a Phase 2 study is a significant milestone for any pharmaceutical company. This suggests that the company is making progress in its research and development efforts, which is typically viewed positively by investors. Therefore, this news is likely to have a positive impact on Cybin's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100